

表 8-2. 肝臓がん、皮膚がん、卵巣がん、尿路系がん、食道がん
女性

(%)

被爆時 年齢	線量 (cGy)											
	5	10	15	20	25	30	35	40	45	50	100	150
0	3.9	7.5	10.9	14.0	16.9	19.6	22.1	24.5	26.8	28.9	44.8	54.9
1	3.9	7.4	10.7	13.8	16.7	19.4	21.9	24.3	26.5	28.6	44.5	54.6
2	3.8	7.3	10.6	13.7	16.5	19.2	21.7	24.1	26.3	28.4	44.2	54.3
3	3.8	7.3	10.5	13.5	16.4	19.0	21.5	23.8	26.0	28.1	43.9	54.0
4	3.7	7.2	10.4	13.4	16.2	18.8	21.3	23.6	25.8	27.9	43.6	53.7
5	3.7	7.1	10.3	13.2	16.0	18.6	21.1	23.4	25.6	27.6	43.3	53.4
6	3.6	7.0	10.2	13.1	15.9	18.4	20.9	23.2	25.3	27.4	43.0	53.1
7	3.6	6.9	10.0	13.0	15.7	18.2	20.7	22.9	25.1	27.1	42.7	52.7
8	3.5	6.8	9.9	12.8	15.5	18.1	20.5	22.7	24.9	26.9	42.4	52.4
9	3.5	6.8	9.8	12.7	15.4	17.9	20.3	22.5	24.6	26.6	42.1	52.1
10	3.5	6.7	9.7	12.5	15.2	17.7	20.1	22.3	24.4	26.4	41.8	51.8
11	3.4	6.6	9.6	12.4	15.0	17.5	19.9	22.1	24.2	26.1	41.4	51.5
12	3.4	6.5	9.5	12.3	14.9	17.3	19.7	21.9	23.9	25.9	41.1	51.2
13	3.3	6.5	9.4	12.1	14.7	17.2	19.5	21.6	23.7	25.7	40.8	50.9
14	3.3	6.4	9.3	12.0	14.6	17.0	19.3	21.4	23.5	25.4	40.5	50.6
15	3.3	6.3	9.2	11.9	14.4	16.8	19.1	21.2	23.3	25.2	40.2	50.3
16	3.2	6.2	9.1	11.7	14.3	16.6	18.9	21.0	23.0	25.0	39.9	49.9
17	3.2	6.2	9.0	11.6	14.1	16.5	18.7	20.8	22.8	24.7	39.6	49.6
18	3.1	6.1	8.9	11.5	14.0	16.3	18.5	20.6	22.6	24.5	39.4	49.3
19	3.1	6.0	8.8	11.4	13.8	16.1	18.3	20.4	22.4	24.3	39.1	49.0
20	3.1	6.0	8.7	11.2	13.7	16.0	18.1	20.2	22.2	24.0	38.8	48.7
21	3.0	5.9	8.6	11.1	13.5	15.8	17.9	20.0	22.0	23.8	38.5	48.4
22	3.0	5.8	8.5	11.0	13.4	15.6	17.8	19.8	21.7	23.6	38.2	48.1
23	3.0	5.7	8.4	10.9	13.2	15.5	17.6	19.6	21.5	23.4	37.9	47.8
24	2.9	5.7	8.3	10.7	13.1	15.3	17.4	19.4	21.3	23.1	37.6	47.5
25	2.9	5.6	8.2	10.6	12.9	15.1	17.2	19.2	21.1	22.9	37.3	47.1
26	2.9	5.5	8.1	10.5	12.8	15.0	17.0	19.0	20.9	22.7	37.0	46.8
27	2.8	5.5	8.0	10.4	12.7	14.8	16.9	18.8	20.7	22.5	36.7	46.5
28	2.8	5.4	7.9	10.3	12.5	14.7	16.7	18.6	20.5	22.3	36.4	46.2
29	2.8	5.4	7.8	10.2	12.4	14.5	16.5	18.5	20.3	22.0	36.1	45.9
30	2.7	5.3	7.7	10.1	12.3	14.4	16.4	18.3	20.1	21.8	35.8	45.6

表 9. 年齢・被曝線量別の寄与リスク 副甲状腺機能亢進症

(%)

被曝時 年齢	線量 (cGy)											
	1	2	3	4	5	6	7	8	9	10	30	50
0	19.6	32.8	42.3	49.4	55.0	59.4	63.1	66.1	68.7	70.9	88.0	92.4
1	18.2	30.8	40.0	47.1	52.7	57.2	60.9	64.0	66.7	69.0	87.0	91.8
2	16.9	28.9	37.8	44.8	50.3	54.9	58.7	61.9	64.6	67.0	85.9	91.0
3	15.6	27.0	35.7	42.5	48.0	52.6	56.4	59.6	62.4	64.9	84.7	90.2
4	14.4	25.2	33.6	40.2	45.7	50.3	54.1	57.4	60.2	62.7	83.5	89.4
5	13.3	23.5	31.5	38.0	43.4	47.9	51.8	55.1	58.0	60.5	82.1	88.5
6	12.3	21.8	29.5	35.9	41.1	45.6	49.5	52.8	55.7	58.3	80.7	87.5
7	11.3	20.3	27.6	33.8	38.9	43.3	47.1	50.5	53.4	56.0	79.3	86.4
8	10.4	18.8	25.8	31.7	36.7	41.0	44.8	48.1	51.1	53.7	77.7	85.3
9	9.6	17.5	24.1	29.7	34.6	38.8	42.5	45.8	48.8	51.4	76.0	84.1
10	8.8	16.2	22.4	27.8	32.5	36.6	40.3	43.5	46.4	49.1	74.3	82.8
11	8.1	14.9	20.8	26.0	30.5	34.5	38.1	41.3	44.1	46.8	72.5	81.4
12	7.4	13.8	19.4	24.2	28.6	32.4	35.9	39.0	41.9	44.4	70.6	80.0
13	6.8	12.7	17.9	22.6	26.7	30.4	33.8	36.8	39.6	42.2	68.6	78.5
14	6.2	11.7	16.6	21.0	24.9	28.5	31.7	34.7	37.4	39.9	66.6	76.9
15	5.7	10.8	15.4	19.5	23.2	26.6	29.8	32.6	35.3	37.7	64.5	75.2
16	5.2	9.9	14.2	18.1	21.6	24.9	27.9	30.6	33.2	35.5	62.3	73.4
17	4.8	9.1	13.1	16.7	20.1	23.2	26.0	28.7	31.1	33.4	60.1	71.5
18	4.4	8.4	12.1	15.5	18.6	21.6	24.3	26.8	29.2	31.4	57.9	69.6
19	4.0	7.7	11.1	14.3	17.3	20.0	22.6	25.0	27.3	29.4	55.6	67.6
20	3.7	7.1	10.2	13.2	16.0	18.6	21.0	23.3	25.5	27.5	53.3	65.5
21	3.3	6.5	9.4	12.2	14.8	17.2	19.5	21.7	23.8	25.7	51.0	63.4
22	3.1	5.9	8.7	11.2	13.6	15.9	18.1	20.2	22.1	24.0	48.6	61.2
23	2.8	5.4	7.9	10.3	12.6	14.7	16.8	18.7	20.6	22.3	46.3	59.0
24	2.6	5.0	7.3	9.5	11.6	13.6	15.5	17.3	19.1	20.8	44.0	56.7
25	2.3	4.6	6.7	8.7	10.7	12.5	14.3	16.0	17.7	19.3	41.7	54.4
26	2.1	4.2	6.1	8.0	9.8	11.5	13.2	14.8	16.4	17.9	39.5	52.1
27	1.9	3.8	5.6	7.3	9.0	10.6	12.2	13.7	15.1	16.5	37.3	49.8
28	1.8	3.5	5.1	6.7	8.3	9.8	11.2	12.6	14.0	15.3	35.1	47.5
29	1.6	3.2	4.7	6.2	7.6	9.0	10.3	11.6	12.9	14.1	33.1	45.1
30	1.5	2.9	4.3	5.7	7.0	8.3	9.5	10.7	11.9	13.0	31.0	42.9

表 10. 線量別の寄与リスク 肝硬変

線量 (cGy)	寄与リスク (%)
20	3.5
40	6.7
60	9.7
80	12.6
100	15.3
120	17.8
140	20.1
160	22.4
180	24.5
200	26.5
250	31.0
300	35.1

表 11. 線量別の寄与リスク 子宮筋腫

線量 (cGy)	寄与リスク (%)
5	2.2
10	4.4
15	6.5
20	8.4
25	10.3
30	12.1
35	13.9
40	15.5
45	17.1
50	18.7
100	31.5
150	40.8

発行者 放射線の人体への健康影響評価に関する研究
主任研究者 児玉 和紀

研究班事務局

〒734-8551 広島県広島市南区霞 1-2-3

広島大学医学部 保健学科

連絡担当者 野宗 万喜

TEL: 082-257-5345 FAX: 082-257-5349